CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced participation in the SVB Leerink 10th Annual Global Healthcare Conference set for February 22-26, 2021. The company's management will present on February 25 at 12 PM Eastern Time in Track V.

CymaBay is advancing seladelpar, a therapy for primary biliary cholangitis (PBC), which has received FDA orphan designation and Breakthrough Therapy Designation. These designations highlight the high unmet medical need for treatments in chronic liver diseases.

NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leerink 10th Annual Global Healthcare Conference taking place February 22-26, 2021.

SVB Leerink 10th Annual Global Healthcare Conference
Date:	Thursday, February 25
Time:	12 pm Eastern Time/ Track V
Webcast:	http://ir.cymabay.com/events

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.  CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.

Cautionary Statements

Any statements made in this press release and at the investor conferences referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, its current and future clinical trials and CymaBay’s ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

When is CymaBay participating in the SVB Leerink 10th Annual Global Healthcare Conference?

CymaBay Therapeutics will participate in the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021, presenting on February 25.

What time will CymaBay's presentation at the Global Healthcare Conference take place?

CymaBay's presentation is scheduled for 12 PM Eastern Time on February 25, 2021.

What is seladelpar and its significance for CymaBay?

Seladelpar is a potent, selective PPARδ agonist being developed by CymaBay for treating primary biliary cholangitis (PBC) and has received several FDA and EMA designations.

What designations has seladelpar received from regulatory agencies?

Seladelpar has received orphan designation from the FDA and EMA, as well as Breakthrough Therapy Designation from the FDA.

What are the potential risks mentioned in CymaBay's press release?

Potential risks include uncertainties in product development, clinical trial outcomes, and regulatory approvals, as stated in CymaBay's cautionary statements.